- Home
- XERS vs MFA Comparison
XERS vs MFA Comparison
Compare XERS & MFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | MFA |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.0B |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | XERS | MFA |
|---|---|---|
| Price | $6.27 | $9.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 6 | 6 |
| Target Price | $10.83 | ★ $11.05 |
| AVG Volume (30 Days) | ★ 1.6M | 1.4M |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 14.16% |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $49,590,000.00 | N/A |
| Revenue This Year | $34.37 | N/A |
| Revenue Next Year | $22.86 | $10.02 |
| P/E Ratio | $636.50 | ★ $7.75 |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $4.30 | $8.78 |
| 52 Week High | $10.08 | $10.57 |
Technical Indicators
Market Signals| Indicator | XERS | MFA |
|---|---|---|
| Relative Strength Index (RSI) | 51.90 | 36.37 |
| Support Level | $6.26 | $8.88 |
| Resistance Level | $6.41 | $10.26 |
| Average True Range (ATR) | 0.28 | 0.22 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 28.50 | 1.36 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About MFA MFA Financial Inc.
MFA Financial Inc is a specialty finance company that invests in and finances residential mortgage assets. Its principal business objective is to deliver shareholder value through the generation of distributable income and through asset performance linked to residential mortgage credit fundamentals. The company selectively invests in residential mortgage assets with a focus on credit analysis, projected prepayment rates, interest rate sensitivity and expected return. The company's reportable segments include mortgage-related assets and Lima One.